NCT02253992 2020-10-05
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT02534506 2020-05-18
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02252263 2017-11-01
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT01471210 2017-04-19
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1 Completed
NCT02110082 2017-04-19
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT01775631 2017-03-31
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Bristol-Myers Squibb
Phase 1 Completed
NCT00309023 2015-10-12
Study of BMS-663513 in Patients With Advanced Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00612664 2015-10-12
Phase II, 2nd Line Melanoma - RAND Monotherapy
Bristol-Myers Squibb
Phase 2 Completed
NCT00803374 2011-11-21
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00351325 2009-09-04
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
NCT00461110 2009-09-04
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Bristol-Myers Squibb
Phase 1 Terminated